Although CBD oil has become a trendy cure-all, treatment of epilepsy is the only use that has garnered significant scientific evidence. I am curious if anyone has tried the new CBD oil to control their epilepsy. I have read many great things about it really controlling seizures and maybe trying it. Information about the use of cannabis oil for epilepsy to gain seizure control. The most well known are two cannabinoids: CBD - cannabidiol.
Seizures CBD for
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Voltage-gated sodium NaV channel blockade by plant cannabinoids does not confer anticonvulsant effects per se.
Molecular targets of cannabidiol in neurological disorders. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Cannabidiol in medical marijuana: Cannabidiol mellows out resurgent sodium current. Progress report on new antiepileptic drugs: Neurological disorders in medical use of cannabis: Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. Consroe P, Wolkin A. Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.
Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats. Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy.
An electro-physiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Phytocannabinoids as novel therapeutic agents in CNS disorders.
A critical review of the anti-psychotic effects of cannabidiol: Neural basis of anxiolytic effects of cannabidiol CBD in generalized social anxiety disorder: Walter L, Stella N. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
Neurological aspects of medical use of cannabidiol. Cannabidivarin is anticonvulsant in mouse and rat. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. Pharmacokinetics and pharmacodynamics of cannabinoids. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.
Single dose kinetics of cannabidiol in man. Eur J Clin Pharmacol. Identification of cytochrome P enzymes responsible for metabolism of cannabidiol by human liver microsomes. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: GW Pharma Ltd; [cited Jul 6]. Cannabidiol CBD in Dravet syndrome: Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P 2C Cannabinoids and cytochrome P interactions. Neuropsychiatric and general interactions of natural and synthetic cannabinoids with drugs of abuse and medicines.
The utility of cannabidiol in the treatment of refractory epilepsy. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Complex pharmacology of natural cannabinoids: Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Does cannabidiol protect against adverse psychological effects of THC? Cannabidiol in patients with treatment-resistant epilepsy: Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.
Cannabinoids in treatment-resistant epilepsy: Anticonvulsant nature of marihuana smoking. Complex partial seizure symptoms affected by marijuana abuse. A case report and review of the literature. Marijuana use in adults admitted to a Canadian epilepsy monitoring unit. Marijuana use and epilepsy: Marijuana use and the risk of new onset seizures.
Trans Am Clin Climatol Assoc. Grand mal convulsions subsequent to marijuana use. Cannabis and other illicit drug use in epilepsy patients. The legal status of cannabis marijuana and cannabidiol CBD under U. Cannabinoid dose and label accuracy in edible medical cannabis products.
Food and Drug Administration. Food and Drug Administration; [cited Jun 26]. The health effects of cannabis and cannabinoids: National Academy Press; Hausman-Kedem M, Kramer U. Efficacy of medical cannabis for treatment of refractory epilepsy in children and adolescents with emphasis on the Israeli experience. Isr Med Assoc J. Maa E, Figi P. The case for medical marijuana in epilepsy. Porter BE, Jacobson C.
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: An Australian nationwide survey on medicinal cannabis use for epilepsy: Report from a survey of parents regarding the use of cannabidiol medicinal cannabis in Mexican children with refractory epilepsy.
Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. CBD-enriched medical cannabis for intractable pediatric epilepsy: Perucca E, Wiebe S.
Not all that glitters is gold: Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. South Afr Med J. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant.
Gloss D, Vickrey B. Cochrane Database Syst Rev. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.
Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Cannabidiol in patients with intractable epilepsy due to TSC: Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome FIRES in the acute and chronic phases. Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome. Saade D, Joshi C. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: Impact of ADHD and cannabis use on executive functioning in young adults.
Adverse health effects of marijuana use. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: Wolff V, Jouanjus E. But cannabis oil that contains THC at higher levels more than 0. THC is a schedule 1 drug , that is to say, it is deemed to have no medicinal value. There is good evidence in robust human clinical trials that CBD is of benefit for specific epilepsies, such as Dravet syndrome and Lennox Gastaut syndrome.
An advantage for the pharmaceutical industry is that these rare diseases with no cure can be fast-tracked for drug development. If so, Epidiolex is likely to be available in US by late European approval is likely to follow. It should be noted that Epidiolex is designed as standardised oral solution of pure plant-derived CBD. It is not the same as the non-standardised, viscous CBD oils that contain varying amounts of CBD and can be purchased in health food shops. There is currently no good evidence that formulations of CBD oil or indeed cannabis oil are as effective on epilepsy seizures.
Equally, there is no robust evidence — just anecdotal reports — that THC helps reduce epilepsy seizures human. In [animal studies], THC has weak overall effects in reducing seizures and has also been shown to be a less effective anticonvulsant than CBD. We now need to decide if we should expand human trials with better defined THC-containing cannabis oil, or if we should focus on CBD.
The specialist will discuss all other treatment options with you first before considering a cannabis-based product. A prescription for medicinal cannabis would only be given when all other treatment options have been tried or are considered unsuitable, and would only be given if the doctor considers it to be in your best interests. MHRA is working with individual companies to ensure that CBD-based products that make medicinal claims should be licensed and meet safety, quality and efficacy standards to protect public health.
To date, the MHRA has licensed no other cannabis based medicinal products as medicines. Skip to main content. In this section What is epilepsy? Diagnosing epilepsy Epileptic seizures Treatment Medication for epilepsy Ketogenic diet Vagus nerve stimulation therapy Epilepsy surgery Deep brain stimulation Care and treatment: Cannabis oil for epilepsy. What is medicinal cannabis? The Government has defined a cannabis-based product for medicinal use in humans as one that: What does the guidance say?
The guidance states that non-licensed medicinal cannabis should only be considered for children who: What is the evidence? What is the evidence around THC? Getting a prescription for medicinal cannabis Cannabis-based medicinal products can only be prescribed by a specialist.
Epilepsy & Seizure Disorders: Cannabinoids and CBD Research Overview
NEW ORLEANS -- About one-third of patients who used cannabidiol (CBD) to manage treatment-resistant epilepsy developed tolerance to it. A collection of published research articles, videos, and other educational resources about epilepsy and CBD (cannabidiol). A brand of cannabidiol (CBD) was approved in June for treatment of epilepsy by the United States Food and Drug Administration (FDA).